P11 Characteristics and long-term real-world outcomes of severe asthma patients treated with benralizumab in the United Kingdom; the BPAP study. (11th November 2022)

• Record Type: Journal Article
• Authors: Jackson, DJ; Burhan, H; Menzies-Gow, A; Rupani, H; Pfeffer, PE; Clifton, IJ; Faruqi, S; Nanzer, AM; Dhariwal, J; Morris, T; Lipworth, J; Watt, M
• Is Part Of: Thorax. Volume 77(2022)Supplement 1
• Page Start: A86
• Page End: A87
• Publication Date: 2022-11-11
• Subjects: Chest -- Diseases -- Periodicals; Thorax; Chest -- Diseases; Periodicals; Periodicals; 617.54
• DOI: 10.1136/thorax-2022-BTSabstracts.147
• Languages: English
• ISSNs: 0040-6376

Abstract

Abstract : Introduction and Objectives: Benralizumab is indicated as an add-on maintenance treatment in adult patients with severe eosinophilic asthma (SEA) that is inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists. Real-world clinical outcomes following 1-year of treatment with benralizumab in the United Kingdom (UK) have been previously described in the Benralizumab Patient Access Programme (BPAP) study; however, longer-term outcomes are unknown. Herein we report results from an extended follow-up period of two years for the BPAP study cohort. Methods: The BPAP study is a multi-centre, retrospective, observational study of patients with SEA from eight UK centres. Data were collected between May 2019 and October 2021 from the medical records of patients receiving their first benralizumab dose between April 2018 and November 2019. Outcomes were assessed using descriptive statistics at baseline, 1 year and 2 years post-benralizumab initiation. Results: A total of 276 patients were included: 62% (171/276) were female and mean (SD) age at asthma onset was 31.4 (18.5) years. In total, 49% (134/276) of patients had atopic asthma, 75% (104/138) had adult-onset asthma, and 21% (57/276) had nasal polyposis. At baseline, the median (IQR) FeNO count was 65.0 (36.0–99.0) ppb and the median (IQR) peak EOS count was 500.0 (300.0–800.0) cells/mcL. The mean (95%CI) annualised exacerbation rate (AER) reduced from baseline by 79% from 5.3 (4.8–5.7) to 1.1 (0.9–1.2) exacerbations/patient/year, with 34% (72/209) of patients totally exacerbation-free at 2 years. At baseline, 63% (174/276) of patients were on maintenance oral corticosteroids (mOCS) for asthma. Of these, 55% (70/127) were mOCS-free at 2 years. Mean (SD) asthma control (ACQ-6) improved from 3.0 (1.5) to 1.6 (1.5) at 2 years with 70% (89/128) achieving the MCID of 0.5. Quality of life [AQLQ] improved from a mean (SD) of 3.4 (1.4) to 4.8 (1.5) at 2 years with 72% of patients achieving the MCID of 0.5 or more. 76% of patients remained on benralizumab at 2 years. Key results are summarised in table 1 . Conclusions: Clinical outcomes up to 2 years post-benralizumab treatment suggest a sustained improvement in all clinical measures including exacerbations, mOCS use, asthma control and health-related quality of life. Please refer to page A213 for declarations of interest related to this abstract.